Cannabis Intoxication, Drug Effects
Conditions
Keywords
Pupillometer, Cannabis Use, Drug Effects, SOBEREYE, OPTOVERA, Pupillary Light Reflex
Brief summary
The goal of this open label study is to evaluate the efficacy of smart phone-based test (SOBEREYE OPTOVERA) on measuring pupillary light reflex (PLR) alterations following cannabis use healthy in adults. The main question it aims to answer is: Can SOBEREYE OPTOVERA detect PLR alterations following cannabis consumption in healthy adults, in comparison to a pupillometer? Participants will be given two 5 mg capsules to be ingested for the 10 mg THC dose or five 5 mg capsules to be ingested for the 25 mg THC. Participants will be asked to complete PLR tests throughout the study day.
Interventions
DRUGTetrahydrocannabinol (10 mg)
10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule
DRUGTetrahydrocannabinol (25 mg)
25 mg of THC provided as a softgel capsule.
DIAGNOSTIC_TESTPupillary Light Reflex (PLR) Test
SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)
DIAGNOSTIC_TESTPupillometer
NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.
Sponsors
KGK Science Inc.
Sobereye Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Open label pilot study
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Males and females 21 years of age or older 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: 1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) 2. Double-barrier method 3. Intrauterine devices 4. Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s) 5. Vasectomy of partner at least 6 months prior to screening 6. Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Self-reported cannabis users based on the Cannabis Use Questionnaire who are familiar and experienced with THC's acute psychoactive effects from the doses and route of administration to be used in this study without previous severe adverse reactions after cannabis ingestion 4. Self-reported cannabis use at least 3x per month but no more than 3x per week 5. Agrees to abstain from cannabis use for 3 days prior to study visit 6. Willingness to complete all assessments associated with the study and agrees to safe transportation home 7. Provided voluntary, written, informed consent to participate in the study
Exclusion criteria
1. Individuals who are pregnant, breast feeding or planning to become pregnant during the study 2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption study products 3. Current and ongoing neurological or ophthalmological issue that could affect the retina (blindness, glaucoma, dry eyes, retinal diseases, pupil abnormalities, cataracts, sensitivity to bright lights) 4. History of surgery on eyes or retinas except for laser corneal surgery 5. Current or history of psychological disorders (e.g., schizophrenia and psychosis) 6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI 7. Type I or Type II diabetes with diabetic retinopathy 8. Unstable metabolic disease or chronic diseases as assessed by the QI 9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (see below) 10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis 11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months 12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI 14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 15. Individuals with an unstable autoimmune disease 16. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI 17. Alcohol or drug abuse within the last 12 months 18. Impairment from illicit drugs or alcohol during their study visit, as assessed by the QI or Sub-Investigator 19. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 20. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (see below) 21. Participation in other research studies 30 days prior to baseline, as assessed by the QI 22. Individuals who are cognitively impaired and/or who are unable to give informed consent 23. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The difference in change in Pupillary Light Reflex (PLR) measures between a smart phone-based test and NeuroLight pupillometer | T=0 to T=5 minutes | The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=5 min. |
| The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer | T=0 to T=30 minutes | The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=30 min. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The difference in change in reaction time | T= 0 at T=60 minutes | The difference in change in reaction time as assessed by Dynavision from T= 0 at T=60 minutes |
| The difference in change in subjective drug effects | T=0 at T= 5 minutes | The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T= 5 min, on a scale of 1 to 10. Higher score indicates higher subjective drug effect. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Clinically relevant post-emergent adverse events | T=0 to T=480 minutes | Clinically relevant post-emergent adverse events at T=0 to T=480 minutes. Including via the modified Drug Effects Questionnaire (DEQ) from T=0 at T=480 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect. |
Countries
Canada
Contacts
Primary ContactErin Lewis, PhD
Outcome results
None listed